Tech Company Financing Transactions

Century Therapeutics Funding Round

Bayer, Fujifilm Cellular Dynamics and Versant Ventures participated in a $250 million funding round for Century Therapeutics. The round was announced on 7/2/2019.

Transaction Overview

Company Name
Century Therapeutics
Announced On
7/2/2019
Transaction Type
Venture Equity
Amount
$250,000,000
Round
Undisclosed
Investors

Bayer (Lead Investor) (Juergen Eckhardt)

Fujifilm Cellular Dynamics (Toshikazu Ban)

Versant Ventures (Carlo Rizzuto)

Proceeds Purpose
The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3675 Market St.
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
www.centurytherapeutics.com
Email Address
Not Recorded
Overview
Century Therapeutics is developing novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies. Our commitment to developing accessible cell therapies provides an unparalleled opportunity to advance the course of cancer care.
Profile
Century Therapeutics LinkedIn Company Profile
Social Media
Century Therapeutics Company Twitter Account
Company News
Century Therapeutics News
Facebook
Century Therapeutics on Facebook
YouTube
Century Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Lalo Flores
  Lalo Flores LinkedIn Profile  Lalo Flores Twitter Account  Lalo Flores News  Lalo Flores on Facebook
Chief Scientific Officer
Luis Borges
  Luis Borges LinkedIn Profile  Luis Borges Twitter Account  Luis Borges News  Luis Borges on Facebook
Chief Technical Officer
Gregory Russotti
  Gregory Russotti LinkedIn Profile  Gregory Russotti Twitter Account  Gregory Russotti News  Gregory Russotti on Facebook
Vice President
Kenneth Dow
  Kenneth Dow LinkedIn Profile  Kenneth Dow Twitter Account  Kenneth Dow News  Kenneth Dow on Facebook
VP - Bus. Development
Janelle Anderson
  Janelle Anderson LinkedIn Profile  Janelle Anderson Twitter Account  Janelle Anderson News  Janelle Anderson on Facebook
VP - Bus. Development
Michael Diem
  Michael Diem LinkedIn Profile  Michael Diem Twitter Account  Michael Diem News  Michael Diem on Facebook
VP - Bus. Development
Adrienne Farid
  Adrienne Farid LinkedIn Profile  Adrienne Farid Twitter Account  Adrienne Farid News  Adrienne Farid on Facebook
VP - Engineering
Michael Naso
  Michael Naso LinkedIn Profile  Michael Naso Twitter Account  Michael Naso News  Michael Naso on Facebook
VP - Finance
Douglas Carr
  Douglas Carr LinkedIn Profile  Douglas Carr Twitter Account  Douglas Carr News  Douglas Carr on Facebook
VP - Human Resources
Shane Williams
  Shane Williams LinkedIn Profile  Shane Williams Twitter Account  Shane Williams News  Shane Williams on Facebook
VP - Manufacturing
Carl Burke
  Carl Burke LinkedIn Profile  Carl Burke Twitter Account  Carl Burke News  Carl Burke on Facebook
VP - R & D
Hy Levitsky
  Hy Levitsky LinkedIn Profile  Hy Levitsky Twitter Account  Hy Levitsky News  Hy Levitsky on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/2/2019: Belong.Life venture capital transaction
Next: 7/2/2019: RealWear venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document every notable VC transaction. VC transactions on this site are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.